Vinge has represented Triton in connection with the sale of Aleris to Mehiläinen Group.

Aleris, headquartered in Stockholm, is a Scandinavian healthcare provider specialising in high-quality specialist care, operating approximately 100 units across Sweden, Norway and Denmark, with around 5,300 employees. Aleris serves approximately 3.8 million patient visits annually within planned surgery, mental health and medical diagnostics. Triton acquired Aleris in 2019 and has since developed the company into a focused specialist healthcare platform with improved clinical quality, reduced waiting times and investments in digital infrastructure. The sale reflects the next step in Aleris’ development and is based on the companies’ shared ambition to further develop specialist care, digital services and clinical quality in the Nordic markets.

The transaction is subject to applicable regulatory approvals.

Vinge’s team consisted mainly of Christina Kokko, Samra Tesser, Kim Bergman, Johanna Barfoed, Maximilian Bengtsson, Chris Bastholm och Sara Eirefors (M&A), Mario Saad, Siri Blomberg, and Filippa Eriksson (Corporate Commercial and IT), Julia Gudmundsson (Banking and finance), Agnes Pigg (Employment), Vilma Simonius, (IP), David Olander (Regulatory), and Emy Rydén (Project Assistant).

Related

Vinge has advised Gamma Waves on Sportway’s EUR 20 million financing round

Vinge has acted as legal adviser to Gamma Waves in connection with Sportway’s EUR 20 million financing round. The round was led by Gamma Waves, together with continued participation from existing shareholders, and values Sportway at approximately EUR 92 million (around SEK 1 billion) post-money.
June 24, 2026

Vinge advises Spotlight Group in connection with offer from Kriptown

Vinge is advising Spotlight Group AB (publ) in connection with Kriptown SAS having made a public cash takeover offer to the shareholders of Spotlight Group
June 17, 2026

Vinge has advised EQT IX in connection with its exit of Beijer Ref AB (publ)

Vinge has advised EQT IX (”EQT”) in connection with the sale of all of its remaining shares of series B in Beijer Ref AB (publ) through an accelerated bookbuilding process carried out on 15 June 2026.
June 16, 2026